全文获取类型
收费全文 | 3922篇 |
免费 | 177篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 34篇 |
妇产科学 | 86篇 |
基础医学 | 723篇 |
口腔科学 | 64篇 |
临床医学 | 316篇 |
内科学 | 877篇 |
皮肤病学 | 70篇 |
神经病学 | 240篇 |
特种医学 | 215篇 |
外科学 | 424篇 |
综合类 | 18篇 |
一般理论 | 4篇 |
预防医学 | 164篇 |
眼科学 | 19篇 |
药学 | 439篇 |
中国医学 | 64篇 |
肿瘤学 | 287篇 |
出版年
2023年 | 21篇 |
2022年 | 61篇 |
2021年 | 133篇 |
2020年 | 69篇 |
2019年 | 82篇 |
2018年 | 102篇 |
2017年 | 69篇 |
2016年 | 116篇 |
2015年 | 179篇 |
2014年 | 193篇 |
2013年 | 228篇 |
2012年 | 364篇 |
2011年 | 334篇 |
2010年 | 210篇 |
2009年 | 177篇 |
2008年 | 241篇 |
2007年 | 256篇 |
2006年 | 225篇 |
2005年 | 213篇 |
2004年 | 143篇 |
2003年 | 132篇 |
2002年 | 93篇 |
2001年 | 98篇 |
2000年 | 69篇 |
1999年 | 69篇 |
1998年 | 28篇 |
1997年 | 15篇 |
1996年 | 25篇 |
1995年 | 15篇 |
1994年 | 10篇 |
1993年 | 9篇 |
1992年 | 21篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 9篇 |
1985年 | 9篇 |
1984年 | 10篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 3篇 |
1978年 | 8篇 |
1973年 | 4篇 |
1972年 | 4篇 |
1971年 | 6篇 |
1970年 | 4篇 |
1968年 | 4篇 |
1961年 | 2篇 |
排序方式: 共有4122条查询结果,搜索用时 171 毫秒
121.
122.
Correction: Self-assembled fibrillar networks comprised of a naturally-occurring cyclic peptide—LOB3
M. A. Rogers Q. Feng V. Ladizhansky D. B. Good A. K. Smith M. Corridini D. A. S. Grahame B. C. Bryksa P. D. Jadhav S. Sammynaiken L.-T. Lim B. Guild Y. Y. Shim P.-G. Burnett M. J. T. Reaney 《RSC advances》2020,10(24):13991
Correction for ‘Self-assembled fibrillar networks comprised of a naturally-occurring cyclic peptide—LOB3’ by M. A. Rogers et al., RSC Adv., 2016, 6, 40765–40776.The authors regret the omission of the following conflict of interest statement.Dr Martin J. T. Reaney is the founder of, and has an equity interest in, Prairie Tide Diversified Inc. (PTD, Saskatoon, SK, Canada: previous company name is Prairie Tide Chemicals Inc.). Dr Youn Young Shim is a Market Consultant for PTD in Korea. The terms of this arrangement have been reviewed and approved by the University of Saskatchewan in accordance with its conflict of interest policies.The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers. 相似文献
123.
124.
Jiyong Kwak Hye-Jin Shin Se-Hoon Kim Jin-Kyoung Shim Ji-Hyun Lee Yong-Min Huh Eui-Hyun Kim Eun-Kyung Park Jong Hee Chang Sun Ho Kim Yong-Kil Hong Dong-Seok Kim Su-Jae Lee Seok-Gu Kang 《Child's nervous system》2013,29(12):2229-2239
Purpose
It has been reported that cancer stem cells (CSCs) can be isolated from primitive neuroectodermal tumor (PNET) specimens. Moreover, mesenchymal stem-like cells (MSLCs) have been isolated from Korean glioma specimens. Here, we tested whether tumor spheres and MSLCs can be simultaneously isolated from a single PNET specimen, a question that has not been addressed.Methods
We isolated single-cell suspensions from PNET specimens, then cultured these cells using methods for MSLCs or CSCs. Cultured cells were analyzed for surface markers of CSCs using immunocytochemistry and for surface markers of bone marrow-derived mesenchymal stem cells (BM-MSCs) using fluorescence-activated cell sorting (FACS). Tumor spheres were exposed to neural differentiation conditions, and MSLCs were exposed to mesenchymal differentiation conditions. Possible locations of MSLCs within PNET specimens were determined by immunofluorescence analysis of tumor sections.Results
Cells similar to tumor spheres and MSLCs were independently isolated from one of two PNET specimens. Spheroid cells, termed PNET spheres, were positive for CD133 and nestin, and negative for musashi and podoplanin. PNET spheres were capable of differentiation into immature neural cells and astrocytes, but not oligodendrocytes or mature neural cells. FACS analysis revealed that adherent cells isolated from the same PNET specimen, termed PNET-MSLCs, had surface markers similar to BM-MSCs. These cells were capable of mesenchymal differentiation. Immunofluorescence labeling indicated that some CD105+ cells might be closely related to endothelial cells and pericytes.Conclusion
We showed that both tumor spheres and MSLCs can be isolated from the same PNET specimen. PNET-MSLCs occupied a niche in the vicinity of the vasculature and could be a source of stroma for PNETs. 相似文献125.
Sonia Franciosi PhD Yaein Shim BSc Margaret Lau BCom Michael R. Hayden MB ChB PhD Blair R. Leavitt MD CM 《Movement disorders》2013,28(14):1987-1994
Treatment effect in Huntington disease (HD) clinical trials has relied on primary outcome measures such as total motor score or functional rating scales. However, these measures have limited sensitivity, particularly in pre‐ to early stages of the disease. We performed a systematic review of HD clinical studies to identify endpoints that correlate with disease severity. Using standard HD keywords and terms, we identified 749 published studies from 1993 to 2011 based on the availability of demographic, biochemical, and clinical measures. The average and variability of each measure was abstracted and stratified according to pre‐far, pre‐close, early, mild, moderate, and severe HD stages. A fixed‐effect meta‐analysis on selected variables was conducted at various disease stages. A total of 1,801 different clinical variables and treatment outcomes were identified. Unified Huntington Disease Rating Scale (UHDRS) Motor, UHDRS Independence, and Trail B showed a trend toward separation between HD stages. Other measures, such as UHDRS Apathy, Verbal Fluency, and Symbol Digit, could only distinguish between pre‐ and early stages of disease and later stages, whereas other measures showed little correlation with increasing HD stages. Using cross‐sectional data from published HD clinical trials, we have identified potential endpoints that could be used to track HD disease progression and treatment effect. Longitudinal studies, such as TRACK‐HD, are critical for assessing the value of potential markers of disease progression for use in future HD therapeutic trials. A list of variables, references used in this meta‐analysis, and database is available at http://www.cmmt.ubc.ca/research/investigators/leavitt/publications . © 2013 International Parkinson and Movement Disorder Society 相似文献
126.
127.
128.
Poly-γ-glutamic acid (PGA), a major component of the bacterial capsule, is known to confer hydrophilicity to bacterial surfaces and protect bacteria from interactions with blood cells. We tested whether applying a bacteriomimetic surface coating of PGA modulates interactions of nanomaterials with blood cells or affects their safety and photothermal antitumor efficacy. Amphiphilic PGA (APGA), prepared by grafting phenylalanine residues to PGA, was used to anchor PGA to reduced graphene oxide (rGO) nanosheets, a model of hydrophobic nanomaterials. Surface coating of rGO with bacterial capsule-like APGA yielded APGA-tethered rGO nanosheets (ArGO). ArGO nanosheets remained stable in serum over 4?weeks, whereas rGO in plain form precipitated in serum within 5?minutes. Moreover, ArGO did not interact with blood cells, whereas rGO in plain form or as a physical mixture with PGA formed aggregates with blood cells. Mice administered ArGO at a dose of 50?mg/kg showed 100% survival and no hepatic or renal toxicity. No mice survived exposure at the same dose of rGO or a PGA/rGO mixture. Following intravenous administration, ArGO showed a greater distribution to tumors and prolonged tumor retention compared with other nanosheet formulations. Irradiation with near-infrared light completely ablated tumors in mice treated with ArGO. Our results indicate that a bacteriomimetic surface modification of nanomaterials with bacterial capsule-like APGA improves the stability in blood, biocompatibility, tumor distribution, and photothermal antitumor efficacy of rGO. Although APGA was used here to coat the surfaces of rGO, it could be applicable to coat surfaces of other hydrophobic nanomaterials. 相似文献
129.
Jae-Uoong Shim Joon-Haeng Rhee Ji-Ung Jeong Young-Il Koh 《Allergy, asthma & immunology research》2016,8(3):206-215
PurposeInvariant natural killer T (iNKT) cells play a critical role in the pathogenesis of asthma. We previously reported the association between circulating Th2-like iNKT cells and lung function in asthma patients and the suppressive effect of Toll-like receptor 5 ligand flagellin B (FlaB) on asthmatic in a mouse model. Thus, we investigated whether FlaB modulates the function of circulating iNKT cells in asthmatic patients.MethodsPeripheral blood mononuclear cells (PBMCs) were treated with FlaB, and the secreted and intracellular cytokines of iNKT cells were evaluated by using ELISA and flow cytometry, respectively, following stimulation with α-galactosylceramide. Foxp3+ iNKT cells were also measured. To determine the effect of FlaB-treated dendritic cells (DCs) on iNKT cells, we co-cultured CD14+ monocyte-derived DCs and T cells from patients with house dust mite-sensitive asthma and analyzed intracellular cytokines in iNKT cells.ResultsA reduction of IL-4 and IL-17 production by iNKT cells in PBMCs after FlaB treatment was alleviated following blocking of IL-10 signaling. A decrease in the frequencies of IL-4+ and IL-17+ iNKT cells by FlaB-treated DCs was reversed after blocking of IL-10 signaling. Simultaneously, an increase in Foxp3+ iNKT cells induced by FlaB treatment disappeared after blocking of IL-10.ConclusionsFlaB may inhibit Th2- and Th17-like iNKT cells and induce Foxp3+ iNKT cells by DCs via an IL-10-dependent mechanism in asthmatic patients. In patients with a specific asthma phenotype associated with iNKT cells, FlaB may be an effective immunomodulator for iNKT cell-targeted immunotherapy. 相似文献
130.
PURPOSE: This study aimed to evaluate the cancer detection rate in a Korean population with prostate-specific antigen (PSA) levels greater than or equal to 20.0 ng/mL. MATERIALS AND METHODS: A total of 174 men 50 to 79 years old (median 69) included in the study. The median prostate volume of the patients was 44.8 mL (range 14.1 to 210.0) and their serum PSA ranged from 20.0 to 9725.0 ng/mL (median 44.8). RESULTS: Of 174 men 141 (81.0%) were diagnosed with prostate cancer on initial biopsy. In the total number of patients, the positive predictive value (PPV) was 62.9% for PSA 20 to 29.9, 72.7% for PSA 30 to 39.9 and 100% for PSA 40 to 49.9 ng/mL. In patients with an abnormal digital rectal examination (DRE), the values for these PSA ranges increased to 89.5%, 91.7% and 100%, respectively. The PPV was 81.0% for PSA cutoff of 20, 89.2% for a cutoff of 30, 95.4% for a cutoff of 40, and 94.7% for a cutoff of 50 ng/mL. In conjunction with an abnormal DRE, the values for these PSA cutoffs increased to 95.9%, 98.1%, 100%, and 100%, respectively. CONCLUSION: Our data suggest the ability to predict the presence of prostate cancer reliably on initial biopsy when PSA threshold is greater than or equal to 50 ng/mL. This PSA threshold may be lowered to 40 ng/mL in the presence of an abnormal DRE. In Korean men with high PSA, the detection rate of prostate cancer on biopsy appears to be comparable to that for American men. 相似文献